BJDX
Bluejay Diagnostics, Inc. · Healthcare
2.05
0.49%(-0.01)
Close2.50
21.95%(+0.45)
After HoursLast Updated: — ET
52W L: $1.6552W H: $16.68
$2.05
CHG+0.19 (+10.22%)
H$2.15
L$1.62
VOL475K
BJDX (1h)
Bluejay Diagnostics, Inc. · Healthcare
ACTON, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (“Bluejay” or the “Company”), a medical diagnostics company focused on rapid, near-patient testing, today announced the successful enrollment of 624 patients in its ongoing SYMON-II Trial, a pivotal clinical study evaluating the Company's Symphony™ platform for interleukin-6 (IL-6) testing in critical care settings to determine patient acuity for sepsis triage and monitoring.
Coloplast A/S (OTCMKTS:CLPBY - Get Free Report) and Bluejay Diagnostics (NASDAQ: BJDX - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, dividends and risk. Volatility and Risk Coloplast A/S has a beta
New clinical data from the SYMON-I study to evaluate IL-6 and organ dysfunction in sepsis patients to be presented. New clinical data from the SYMON-I study to evaluate IL-6 and organ dysfunction in sepsis patients to be presented.
NEWPORT BEACH, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- NorthStrive Fund II LP (“NorthStrive Fund”), a subsidiary of NorthStrive Companies Inc., today issued an open letter to the Board of Directors and shareholders of Bluejay Diagnostics, Inc. (“Bluejay” or the “Company”) recommending the Board evaluate a strategic opportunity that NorthStrive believes could significantly enhance long-term shareholder value.
ACTON, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics (NASDAQ: BJDX) today announced that as of February 19, 2026, all of the prefunded warrants issued by the Company in its October 2025 private placement have been fully exercised, and the Company has no remaining prefunded warrants of any class or tranche outstanding. Following these exercises, the Company now has approximately 972,000 shares of common stock outstanding. In addition, the Company has cash exercisable warrants outstanding for approximately 1.5 million shares. All such warrants have a cash exercise price of $7.00 or greater per share.
ACTON, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics (NASDAQ: BJDX) today announced that it has successfully enrolled 545 patients in its SYMON™ II multicenter clinical study and has made substantial progress in advancing manufacturing readiness and technology transfer initiatives into 2026, representing a key execution milestone as the Company transitions from clinical enrollment toward data analysis, regulatory engagement, and commercialization readiness.
Dey Svetlana
director
500 SH @ $3.07
2023-12-13
Dey Indranil
director, 10 percent owner, officer: President and CEO
500 SH @ $3.27
2023-12-13
Scally Frances P
officer
0 SH @ $0.00
2023-09-26
Dey Svetlana
director
10,000 SH @ $0.44
2023-03-24
Dey Indranil
director, officer: President and CEO
2,000 SH @ $0.44
2023-03-28
Dey Indranil
director, officer: President and CEO
8,000 SH @ $0.44
2023-03-27
Dey Indranil
director, officer: President and CEO
2,000 SH @ $0.44
2023-03-28
Dey Indranil
director, officer: President and CEO
8,000 SH @ $0.44
2023-03-27